Extensive bullous lichenoid drug eruption associated with the combination therapy of enfortumab vedotin and pembrolizumab: A case report

Extensive bullous lichenoid drug eruption associated with the combination therapy of enfortumab vedotin and pembrolizumab: A case report

Saved in:

Bibliographic Details
Main Authors:	Li-Hsin Wang, Chih-Chiang Chen
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-01-01
Series:	Dermatologica Sinica
Online Access:	https://journals.lww.com/10.4103/ds.DS-D-23-00188
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report
by: Roxana A. Hojjatie, BS, et al.
Published: (2025-07-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report
by: Michael Glover, et al.
Published: (2025-03-01)

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab
by: Benjamin Müller, et al.
Published: (2024-11-01)

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances
by: Albert Jang, et al.
Published: (2025-04-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Delayed lichenoid drug eruption associated with apremilast
by: Betty Hinderks-Davis, MD, et al.
Published: (2025-05-01)

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
by: Maura C. Gillis, BA, et al.
Published: (2025-02-01)

Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report
by: Xia M, et al.
Published: (2025-04-01)

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy
by: Zhuo Xing, et al.
Published: (2025-04-01)

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report
by: Ming-Hsuan Wu, et al.
Published: (2024-12-01)

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
by: Takafumi Fukushima, et al.
Published: (2025-07-01)

Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
by: Keita Minami, et al.
Published: (2025-05-01)

Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin
by: John S. Wang, et al.
Published: (2025-02-01)

Lichenoid Drug Eruption Secondary to Growth Hormone in a Case of Noonan’s Syndrome
by: Uffra Shaikh, et al.
Published: (2025-04-01)

Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series
by: Mohammad Jad Moussa, et al.
Published: (2025-05-01)

Bullous fixed drug eruption due to erlotinib: A rare case report
by: Kallolinee Samal, et al.
Published: (2025-07-01)

Stevens–Johnson syndrome-like cutaneous toxicity with enfortumab vedotin in treating metastatic urothelial carcinoma: A case report
by: Yun-Chang Li, et al.
Published: (2024-11-01)

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
by: Grégoire Desimpel, et al.
Published: (2024-11-01)

Capivasertib-induced polymorphous lichenoid exanthem: Report of a novel AKT kinase inhibitor-related drug eruption
by: Raj P. Fadadu, MD, MS, et al.
Published: (2025-08-01)

Bullous Eruption with Cholestasis in Pregnancy
by: Sara Al Janahi, et al.
Published: (2025-06-01)

Enfortumab Vedotin–Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding
by: Aika Matsuyama, et al.
Published: (2025-07-01)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
by: Makito Miyake, et al.
Published: (2023-01-01)

Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy
by: Shota Kaburaki, et al.
Published: (2025-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
by: Mimma Rizzo, et al.
Published: (2025-02-01)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma
by: Suzy Van Sanden, et al.
Published: (2024-08-01)

Cross-Reactivity: a Case of Paracetamol-Induced Generalized Bullous Fixed Drug Eruption Followed by Dipyrone-Induced Fixed Drug Eruption
by: Wang Y, et al.
Published: (2025-04-01)

Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib
by: Andrew Wellen, et al.
Published: (2025-05-01)

Clinical cues for distinguishing bullous fixed drug eruption from Stevens–Johnson syndrome: A case report
by: Luna Samman, et al.
Published: (2024-12-01)

Tense Bullous Eruptions Arising in Porokeratosis: A Quiz
by: Tomoko Hirano, et al.
Published: (2025-07-01)

Generalized bullous fixed drug eruption induced by chlordiazepoxide: a case report of a potentially lethal adverse effect
by: Rishabh Singh, et al.
Published: (2025-04-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan
by: Y. Kita, et al.
Published: (2025-03-01)

Lichenoid drug reaction to technicium-99: a case report and review of the literature
by: Emily Kozera, MD, et al.
Published: (2024-10-01)

Metformin-Induced Generalized Bullous Fixed-Drug Eruption with a Positive Dechallenge-Rechallenge Test: A Case Report and Literature Review
by: Bahareh Abtahi-Naeini, et al.
Published: (2023-01-01)

Bullous Eruption Following Methoxsalen Treatment in a Pediatric Patient with Vitiligo Vulgaris
by: Shekhar Neema, et al.
Published: (2025-01-01)

Antiretroviral Drug-Associated Oral Lichenoid Reaction in HIV Patient: A Case Report
by: Pratanporn Arirachakaran, et al.
Published: (2010-01-01)

Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature
by: Elie S. Bterrani, et al.
Published: (2025-07-01)

Keratoacanthoma-like eruption associated with pembrolizumab and dupilumab treated by intralesional triamcinolone: A case report
by: Raphaella Lambert, BA, et al.
Published: (2025-07-01)